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Abstract
Background
Dengue is one of the fastest spreading vector-borne diseases, caused by four antigenically
distinct dengue viruses (DENVs). Antibodies against DENVs are responsible for both pro-
tection as well as pathogenesis. A vaccine that is safe for and efficacious in all people irre-
spective of their age and domicile is still an unmet need. It is becoming increasingly
apparent that vaccine design must eliminate epitopes implicated in the induction of infec-
tion-enhancing antibodies.
Methodology/principal findings
We report a Pichia pastoris-expressed dengue immunogen, DSV4, based on DENV enve-
lope protein domain III (EDIII), which contains well-characterized serotype-specific and
cross-reactive epitopes. In natural infection, <10% of the total neutralizing antibody
response is EDIII-directed. Yet, this is a functionally relevant domain which interacts with
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the host cell surface receptor. DSV4 was designed by in-frame fusion of EDIII of all four
DENV serotypes and hepatitis B surface (S) antigen and co-expressed with unfused S anti-
gen to form mosaic virus-like particles (VLPs). These VLPs displayed EDIIIs of all four
DENV serotypes based on probing with a battery of serotype-specific anti-EDIII monoclonal
antibodies. The DSV4 VLPs were highly immunogenic, inducing potent and durable neutral-
izing antibodies against all four DENV serotypes encompassing multiple genotypes, in mice
and macaques. DSV4-induced murine antibodies suppressed viremia in AG129 mice and
conferred protection against lethal DENV-4 virus challenge. Further, neither murine nor
macaque anti-DSV4 antibodies promoted mortality or inflammatory cytokine production
when passively transferred and tested in an in vivo dengue disease enhancement model of
AG129 mice.
Conclusions/significance
Directing the immune response to a non-immunodominant but functionally relevant sero-
type-specific dengue epitope of the four DENV serotypes, displayed on a VLP platform, can
help minimize the risk of inducing disease-enhancing antibodies while eliciting effective tet-
ravalent seroconversion. DSV4 has a significant potential to emerge as a safe, efficacious
and inexpensive subunit dengue vaccine candidate.
Author summary
Dengue is mosquito-borne viral disease which is currently a global public health problem.
It is caused by four different types of dengue viruses. Nearly a 100 million people a year
suffer from overt sickness, which may range from mild fever to potentially fatal disease. A
virus-based dengue vaccine was launched for the first time in late 2015. Unexpectedly,
this vaccine mimics the dengue viruses in that it appears to elicit disease-enhancing anti-
bodies. To reduce such risk, safer vaccines that eliminate viral proteins responsible for
undesirable antibodies are needed. We focused our attention on a small domain of the
dengue virus surface protein known as envelope domain III (EDIII). Humans make only
a small amount of antibodies against EDIII, but these antibodies are effective in blocking
dengue virus from entering cells. We used a yeast expression system to display EDIIIs of
all four types of dengue viruses on the surface of non-infectious virus-like particles
(VLPs). These VLPs elicited antibodies, in mice and monkeys, which blocked all four den-
gue virus types and their variants from entering cells in culture. Importantly, these anti-
bodies did not enhance dengue infection in a mouse model.
Introduction
Dengue is a viral disease spread to humans primarily through mosquito vectors of the genus
Aedes. The disease is prevalent in >100 tropical and sub-tropical countries of the globe, and is
estimated to cause ~390 million infections annually [1]. It is regarded by the World Health
Organization (WHO) as one of the fastest spreading vector-borne diseases [2]. Dengue virus
(DENV), the etiological agent that causes dengue belongs to the genus Flaviviruswithin the
family Flaviviridae [3]. There are four antigenically distinct DENV serotypes (DENV-1,
DENV-2, DENV-3 and DENV-4), which differ at the amino acid (aa) level in the viral
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envelope by 25–40% [4]. Each DENV serotype is comprised of multiple genotypes, which
manifest up to 3% differences at the aa level [4, 5].
While in the majority of cases, DENV infection is asymptomatic it can cause symptomatic
disease in ~25% cases [1]. This can range from mild dengue fever to severe and potentially
fatal dengue hemorrhagic fever and dengue shock syndrome [6]. Severe dengue disease tends
to correlate with a heterotypic secondary DENV infection and is held to be the outcome of
antibody dependent enhancement (ADE). Antibodies against the primary infecting DENV
serotype are unable to neutralize the secondary DENV serotype, but opsonize it and mediate
increased infectivity of Fc gamma receptor (FcγR)-bearing monocytes and macrophages to
drive up virus production [7]. The ADE hypothesis has provided the rationale for current
thinking that a successful dengue vaccine should be capable of inducing strongly neutralizing
antibodies (nAbs) to all four DENV serotypes simultaneously [8]. The implicit assumption in
this approach that it would circumvent ADE has been belied by phase III trial data [9, 10] and
long term safety monitoring of Dengvaxia [11], a live attenuated tetravalent chimeric dengue
vaccine. This vaccine was recently approved for use only in adults in regions of high dengue
prevalence, where it is projected to bring about a 30% reduction in dengue burden over a thirty
year period [12]. Based on the increased hospitalization of younger children, who were found
to be seronegative at the time of receiving Dengvaxia, it is now believed that it can simulate a
primary DENV infection in seronegative individuals. This could potentially sensitize them to
ADE when they encounter a natural DENV infection [13, 14]. It is becoming increasingly evi-
dent that the quality of the antibodies elicited by a candidate dengue vaccine is more important
than previously realized. This situation warrants the exploration of alternate approaches to
dengue vaccine design and development.
The human antibody response to DENV infection tends to be primarily focused towards
the generation of weakly-neutralizing and cross-reactive antibodies against the viral structural
proteins, pre-membrane (prM) and envelope (E) [15–17]. The prM protein is required for
proper folding of the E protein, which is involved in mediating host receptor recognition and
fusion of the host and viral membranes [3]. Anti-prM and anti-E antibodies, particularly those
that are specific to the fusion-loop (FL) epitope, enhance rather than ablate DENV infection
[18–21]. On the other hand, a subset of human DENV-nAbs has been shown to target complex
quaternary epitopes discernible only on the mature virion surface [22–25]. Interestingly, some
DENV-nAbs also target a carboxy-terminally located domain of the E protein known as enve-
lope domain III (EDIII) [26], which contains multiple dengue complex and serotype-specific
neutralizing epitopes [27–29]. Several studies strongly suggest that the host receptor recogni-
tion function of the E protein maps to EDIII [30–32], which is discernible on the mature virion
surface [33] as well as on recombinant E protein [34, 35]. The accessibility of EDIII on the
virion surface is also corroborated by the inclusion of some of its aa residues in the footprint
of quaternary epitope-recognizing DENV-neutralizing human monoclonal antibodies (mAbs)
[23, 25]. Recent work shows that a mAb engineered to bind efficiently to EDIIIs of all four
DENVs can abrogate severe dengue disease in a humanized mouse model [36]. Thus, EDIII
offers a relatively simple but functional epitope, in comparison to the quaternary epitopes
mentioned above. In addition an EDIII-based dengue vaccine holds promise of safety, as it
eliminates prM and the rest of the E protein responsible for eliciting antibodies with ADE
potential. Interestingly, while the anti-EDIII mAbs have been found to be potent blockers of
DENV infectivity [31, 36], they constitute only a minor fraction of the human anti-DENV
antibody repertoire [37].
Our work is driven by the hypothesis that an EDIII-based dengue vaccine would not only
elicit potent DENV-nAbs but also may help minimize ADE risk. But this would be feasible, if
the immunogenicity of EDIII could be augmented. One way to accomplish this would be to
display it on the surface of virus-like particles (VLPs). In this context, it is well-documented
that the surface antigen (S) of Hepatitis B Virus (HBV), the main component of commercial
HBV vaccine, expressed in a recombinant host system, possesses an inherent propensity to
self-assemble into VLPs [38–40]. Thus, we designed and created a recombinant Dengue Sub-
unit Virus-like particle tetravalent (DSV4) vaccine candidate based on the HBV S antigen VLP
platform, using the methylotrophic yeast Pichia pastoris as the expression system. The design
of DSV4 was based on two key observations made earlier. In one study, we demonstrated the
feasibility of creating an EDIII-based tetravalent antigen by fusing the EDIIIs of the four
DENV serotypes ‘in-frame’ via flexible peptide linkers [41]. In subsequent work, we showed
that HBV S antigen when co-expressed with DENV-2 EDIII fused ‘in-frame’ to the S antigen
(in 4:1 ratio), using the P. pastoris host, self-assembled into stable mosaic DENV-2 EDIII-dis-
playing VLPs, referred to as ES,S4 [42]. This approach, similar to that utilized for the RTS, S
malaria vaccine [43, 44], provided the rationale for co-expressing 4 copies of HBV S antigen
per copy of the EDIII-based tetravalent dengue antigen.
We evaluated the utility of DSV4 as a potential dengue vaccine candidate by investigating:
(i) the accessibility and antigenic integrity of EDIII of the four DENV serotypes on DSV4; (ii)
the immunogenicity of DSV4 in mice and macaques and its ability to achieve tetravalent sero-
conversion; and (iii) the protective or enhancing potential of DSV4-induced antibodies in an
in vivo animal model. Our findings provide proof-of-concept data supporting the utility of




All the experiments using BALB/c mice were conducted at Syngene International Limited,
Bangalore (IAEC No. Syngene/IAEC/520/06-2014), in compliance with the guidelines of the
Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA)
of the Government of India. Experiments using AG129 mice (obtained from Dr. Sujan Shresta,
La Jolla Institute for Allergy and Immunology, CA, USA) were performed at Global Vaccines
Inc. (GVI), North Carolina, USA, according to GVI’s Institutional Animal Care and Use Com-
mittee (IACUC) protocol. AG129 mice experiments were also carried out at ICGEB, New
Delhi, in compliance with ICGEB’s Institutional Animal Ethical Committee guidelines and
approval. The NHP studies were performed at Emory University. All animals were housed and
maintained at the Yerkes National Primate Research Center (YNPRC) of Emory in accordance
with the rules and regulations of the Committee on the Care and Use of Laboratory Animal
Resources and in accordance with the Weatherall report. Prior to the initiation of the study,
the local IACUC approved the entire study including the immunization and collection of sam-
ples, which were done under sedation to minimize stress and pain. All the animals were pro-
vided water ad libitum, and monkey chow (Purina) supplemented daily with fresh fruit or
vegetable for enrichment. The well-being of the animals was monitored daily by animal care
and veterinary staff and managed by the Yerkes team. The YNPRC is fully accredited by AAA-
LAC International.
Cell lines, DENVs, anti-EDIII serotype-specific mAbs and other reagents
Cells, viruses, antibodies and other reagents were obtained from different sources as described
in supplementary materials (S1 Appendix). DENV stock titers were determined using a Fluo-
rescence Activated Cell Sorting (FACS) assay [45]. Viral titer was expressed as FACS infectious
units (FIU)/ml infected culture supernatant, and was calculated using the formula, FIU/ml =
[(% infected cells) x (total number of cells in well) x (dilution factor)]/(volume of virus inocu-
lum) [45].
DSV4 design and gene construction
DSV4 consists of two proteins, DS and S. The DS protein, encoded by the DS gene (GenBank
accession no. KM229742), codon-optimized for expression in P. pastoris, consists of sequences
encoding ~104 aa each of EDIII-1, -3–4 and -2 (corresponding to DENV-1 West Pac-74,
DENV-3 H87/56, DENV-4 H241-P and DENV-2 PR159-S1/69, respectively) and 226 aa of S
antigen (HBV adw serotype), linked in tandem through nucleotide sequences encoding hexa-
glycyl linkers, in the order mentioned. The DS gene was custom-synthesized and made avail-
able in the P. pastoris vector pPICZa (by DNA2.0 Inc., USA), in which it is flanked on the 5’
and 3’ sides by the P. pastoris AOX1 promoter and transcription terminator, respectively.
The DS expression cassette was excised from this construct as a Bgl II-Bam HI fragment and
inserted into the Bam HI site of 4S-pAO815, a plasmid containing four copies of the S antigen
expression cassette [42], to generate the construct DSV4-pAO815 (S1 Fig, panels A-D). This
vector was then electroporated into P. pastoris GS115 strain (Invitrogen, Thermo Fischer Sci-
entific, USA) and transformants selected on plates lacking histidine [42].
Recombinant DSV4 expression and localization
Yeast cultures were grown at 30˚C in buffered glycerol-containing medium (BMGY), and
DSV4 expression induced by replacing BMGY with methanol-containing buffered medium, as
described earlier [42]. For localization studies, total (T) lysates were prepared and fractionated
into membrane-enriched pellet (P) and supernatant (S) fractions. DSV4 in the ‘T’, ‘S’ and
urea-solubilized ‘P’ fractions were analyzed by SDS-PAGE followed by silver staining, Western
blotting and ELISA using EDIII-specific mAb 24A12 [46] and S antigen-specific mAb 5S as
reported earlier [40].
Purification of recombinant DSV4
DSV4 was purified from induced biomass (~50 g) obtained after 3 days of 2% methanol-induc-
tion using a slight modification of our previously described protocol [42] for ES,S4 VLPs (sup-
plementary methods, S1 Appendix).
DSV4 physical characterization
The presence of DS and S proteins in DSV4 was analyzed by SDS-PAGE followed by silver
staining. The identity of DS and S proteins was confirmed in immunoblots and ELISAs using
EDIII-specific mAb 24A12 [46] and S-specific mAb 5S [40]. The relative ratio of DS and S pro-
teins was determined by densitometric analysis of the Western blot of purified DSV4 devel-
oped with mAb 5S. The relative ratio was calculated from the peak area of histogram obtained
for DS, S and S dimer using ImageJ software developed by NIH (https://imagej.nih.gov/ij/).
Assembly of DSV4 into higher order particulate structures was analyzed by size exclusion
chromatography using Superose 6 10/300 GL column (GE Life Sciences, Chicago, USA) and
electron microscopy, using uranyl acetate for negative staining. The size distribution profile of
DSV4 particles was analyzed by dynamic light scattering (DLS) using Zetasizer Nano Z (Mal-
vern instruments, Malvern, UK).
Antigenic integrity of EDIII epitopes on DSV4 VLPs was assessed using a sandwich ELISA.
In this assay DSV4 VLPs were captured using different anti-DENV mAbs and revealed using
anti-S antigen mAb-horse radish peroxidase (HRPO) conjugate (from Hepnostika HBsAg
Ultra micro ELISA kit). The protocol used was essentially similar to that reported before [42]
with slight modifications as described in S1 Appendix.
Animal immunization
Mouse immunization: For routine immunization, each BALB/c mouse was immunized intra-
muscularly (i.m.) with 20 μg of DSV4 adsorbed on 500 μg alhydrogel on days 0, 30 and 90. In
one early experiment, two additional mouse strains (C57BL-6 and C3H) were also immunized
with DSV4 using the same dose and schedule, with the exception that the vaccine was formu-
lated using alhydrogel and monophosphoryl lipid A (MPLA). In most experiments, the num-
ber of mice per group was 6. Specific mice numbers are indicated at the appropriate places. As
the S: DS ratio in DSV4 VLPs is 4:1, the 20 μg dose, equivalent to 4 μg DS, would provide just
under 1 μg of EDIII per DENV serotype. Sera were collected on day 105 for evaluation of anti-
body titers by ELISA and FACS-based virus-neutralization assay and passive transfer studies.
For passive transfer experiments, anti-DENV-2 and anti-DENV-4 antisera were raised in
BALB/c mice following multiple immunizations with the cognate live viruses.
Macaque immunization: Macaques in one group (n = 6) were immunized (i.m.) with DSV4
(100 μg/macaque) adsorbed on alhydrogel (500 μg) mixed with MPLA (100 μg), on days 0, 28
and 84. The macaque dose was chosen to provide ~4 μg of EDIII per DENV serotype. A sec-
ond group (n = 6) received the same dose of DSV4 formulated in alhydrogel alone without
MPLA. Sera were collected on days 42, 84, 98 and 119. Anti-TViDV antiserum for in vivo
ADE assay (see below) was raised by immunizing macaques twice with a mixture of inactivated
DENVs 1–4 (5 μg each) formulated in GVI3000 adjuvant.
Seroanalysis
Indirect ELISA to detect antibodies directed against each of the five constituents of DSV4 vac-
cine and FACS-based neutralization test for determining DENV-neutralizing titers in anti-
DSV4 antisera were performed using mAb 2H2-Alexa 488 conjugate to identify DENV-
infected Vero cells, as described [47]. Serum dilution resulting in 50% reduction in the number
of DENV-infected cells with reference to the number of cells infected by DENV in absence of
immune serum was defined as the FACS-based Neutralization Titer causing 50% inhibition of
DENV infectivity (FNT50 titer). In vitro ADE assays were performed using K562, as reported
[35].
AG129 mouse challenge experiments
The ADE potential and protective efficacy of DSV4-induced antibodies were tested by either
sub-lethal challenge with DENV-2 S221 (5x103 FIU) or lethal challenge with DENV-4 strain
703–4 (108 FIU), respectively, following passive transfer of anti-DSV4-antisera and control
sera/mAb into AG129 mice. The sub-lethal (DENV-2 S221) and lethal (DENV-4, 703–4) dos-
ages were pre-determined in early dose-optimization experiments. Viremia was determined
on post-challenge day 3 by real time PCR analysis after reverse transcription. In some ADE
experiments [48], DENV-2 S221 (2x104 FIU) was partially or fully pre-neutralized with differ-
ent antibodies/antisera and the resultant immune complexes (ICs) inoculated into AG129
mice (n = 9). A subset of these animals (n = 3) was euthanized on post-IC inoculation day 3 for
the determination of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in small intes-
tinal tissue homogenates as described (S1 Appendix). Prior monitoring of the kinetics of vire-
mia showed that levels are maximal on post-challenge days 2 and 3. Mortality/morbidity of
challenged mice was monitored to generate Kaplan-Meir survival curves as described.
Statistical analyses
Two-tailed Student t test and Mann-Whitney test were used to determine statistical signifi-
cance of the difference between data sets. Kaplan-Meier survival curves were analyzed by the
Log-Rank test for significance. Probability (p) levels less than 0.05 were considered as signifi-
cant. All statistical calculations were performed using GraphPad Prism software (version 7a).
Results
DSV4 assembles into VLPs displaying EDIIIs of all four DENV serotypes
We created DSV4 VLPs by fusing the EDIII-based tetravalent antigen to the HBV S antigen
(DS antigen) and co-expressing it with four copies of S antigen in P. pastoris (Fig 1A, S1 Fig,
panels A-D). Co-expressed DS and S proteins in P. pastoris were associated with the mem-
brane-enriched ‘P’ fraction of methanol-induced lysates (S1 Fig, panels E & F). After optimiza-
tion of conditions for methanol-induced expression (S1 Fig, panels G & H), DSV4 was
purified by hydrophobic interaction chromatography (S2 Fig, panel A) and analyzed by
SDS-PAGE and immunoblotting with mAbs specific to its two components (S2 Fig, panel B).
The presence of higher order structures in purified DSV4 was evident based on its elution
as a single peak in the void volume when it was subjected to size exclusion chromatography
(Fig 1B). SDS-PAGE followed by silver staining of the pooled void volume fractions revealed
co-elution of both the protein components of DSV4 (Fig 1B, inset). DLS analysis of this mate-
rial demonstrated the presence of a predominantly homogenous population (98%, PdI = 0.25)
of 20–25 nm sized particles (Fig 1C). Electron microscopic analysis corroborated the presence
of discrete VLPs in the purified DSV4 preparation (Fig 1C, inset).
Next we probed the DSV4 VLPs with a panel of DENV-specific conformation-sensitive
mAbs [16, 21, 29, 49–55]. One of the key serotype-specific neutralizing epitopes on EDIII is
the lateral ridge (LR) epitope [27, 28, 50, 51]. We devised a qualitative sandwich ELISA,
wherein we captured the purified VLPs using different type-specific and cross-reactive murine
and human DENV E-specific mAbs and revealed the bound VLPs using anti-HBV S mAb-
enzyme conjugate. The binding of these mAbs to their specific antigens had been validated in
our recent studies [35]. It is to be noted that none of the dengue mAbs used in this experiment
recognized HBV S VLPs. Thus, a positive signal is recorded only with DSV4 VLPs which are
captured via recognition of the EDIII moiety and revealed through recognition of the S moi-
ety. The data on DSV4 reactivity towards these mAbs are summarized in Table 1. DSV4 VLPs
showed very good reactivity towards several of these mAbs, most of which were specific to the
EDIII-LR epitope. These included type-specific mAbs (which bind to only one serotype), sub-
complex specific mAbs (bind to one or more, but not all DENV serotypes), and complex-spe-
cific mAbs (bind to all four DENV serotypes). This analysis also revealed the presence of addi-
tional EDIII epitopes such as those localized to N-terminal linker, A and B strands, C-C’ loop,
D and G strands. Consistent with its design, the DSV4 VLPs failed to be recognized by a bat-
tery of fusion loop-recognizing human [16, 52, 53] and murine [49] mAbs as well as by a
human anti-prM mAb 2K2 [21]. Collectively, these data led us to the conclusion that the
DSV4 VLPs, produced by co-expressing DS and S antigens in P. pastoris, contain all the five
antigenic components, the EDIIIs corresponding to the four serotypes (EDIII-1, EDIII-2,
EDIII-3 and EDIII-4) and HBV S, consistent with its design (Fig 1A).
The reproducibility of DSV4 purification and its assembly into EDIII-displaying VLPs was
ascertained in multiple experiments (S1 Table; S2 Fig, panel C and adjoining table; S3 Fig, pan-
els A-D). The DSV4 VLPs were stable for>1 year in liquid nitrogen and at -80˚C, 2 months at
4˚C and 1–2 days at 25˚C (S3 Fig, panels E & F; S2 Table).
Fig 1. DSV4 assembles into immunogenic VLPs. (A) Schematic representation of DSV4 antigen construct. Magenta, green, blue, and black blocks represent EDIII-
encoding domains of DENV-1, -2, -3 and -4, respectively (the specific strains are indicated on the top of respective blocks). EDIIIs were linked to each other and to
fusion partner Hepatitis B surface antigen (S; adw serotype; grey colored block), in frame, through hexa-glycyl (G6) linkers to encode Dengue-HBsAg (DS) protein. Four
expression cassettes of S and one expression cassette of DS were assembled in pAO815 vector between Bgl II and Bam HI sites. Each expression cassette consists of 5’
AOX1 promoter (P), the recombinant gene (S or DS) and transcription terminator sequences (T). All the expression cassettes are in tandem, with the black star between
adjacent expression cassettes representing Bgl II-Bam HI fusion site. (B) Elution of purified DSV4 in void volume (grey shaded region) of a Superose 6 column. The
inset shows a silver stained gel picture of the material eluted in the void volume (lane ‘1’) with positions of DS, S and dimer of S indicated by arrows on the right. Protein
size markers were run in lane ‘M’; their sizes (in kDa) are shown on the left. (C) Volume distribution profile of DSV4 using DLS. The left inset shows DLS parameter
values (size, volume and PdI) for peaks 1 and 2. The right inset shows transmission electron microscopic image of DSV4 VLPs. (D) Indirect ELISA reactivity of pooled
serum (n = 6) collected 15 days after completion of immunization of BALB/c mice (immunized on days 0, 30 and 90) with DSV4 adsorbed on alhydrogel. Serum was
analyzed using purified recombinant EDIII-1 (magenta curve), EDIII-2 (green curve), EDIII-3 (blue curve), EDIII-4 (black curve) and HBsAg (grey curve) as capture
antigen. PBS-immunized sera (purple curve) served as negative control. Each data point represents the average of duplicates. (E) Groups (n = 6) of three different mouse
strains (BALB/c, C57BL-6 and C3H) were immunized with DSV4 VLPs as described in methods. A fourth group (n = 6, BALB/c) was immunized with S VLPs to serve
as negative control. DSV4 and S VLPs were formulated in a mixture of alhydrogel plus MPLA for this experiment alone. Immune sera from all groups were analyzed for
nAb titers (FNT50 titers) using the FACS assay against WHO reference strains of DENV-1 (magenta bars), DENV-2 (green bars), DENV-3 (blue bars) and DENV-4
(black bars). Mann-Whitney test-derived p values for DENV-1 (0.130), DENV-2 (0.959), DENV-3 (0.160) and DENV-4 (0.573) indicated no statistically significant
difference in nAb titers between BALB/c and C57BL-6 mice. C3H mice elicited significantly lower nAb titers against DENV-1 (p = 0.007) and DENV-2 (p = 0.004),
compared to BALB/c mice, and against DENV-2 (p = 0.006), compared to C57BL-6 mice.
https://doi.org/10.1371/journal.pntd.0006191.g001
DSV4 VLPs elicit tetravalent serotype-specific nAbs effective against
multiple genotypes in mice
We examined the immunogenicity of DSV4 VLPs in immunocompetent BALB/c mice rather
than AG129 mice, despite the latter’s utility as a dengue model, because it is genetically immu-
nocompromised. Sera collected from BALB/c mice immunized with DSV4 VLPs, formulated
in alhydrogel adjuvant, were analyzed using an indirect ELISA. In this ELISA, we used all four
recombinant EDIII antigens, as well as recombinant S antigen, as the coating antigen, sepa-
rately, and observed that anti-DSV4 antiserum possessed high titers of antibodies against all its
five components (Fig 1D). As we could discern the presence of the potently neutralizing LR
epitope of all four DENV serotypes in DSV4 VLPs (Table 1), we wished to analyze the anti-
DSV4 antiserum for its ability to neutralize the infectivity of WHO reference DENV strains
corresponding to the 4 serotypes, using a FACS based virus-neutralization assay in Vero cells
[47]. As we wanted to assess if DSV4 VLPs would be immunogenic in other murine strains as
well, we immunized two other strains of mice, C57BL-6 and C3H, apart from BALB/c with
DSV4 VLPs (we used MPLA in addition to alhydrogel as adjuvants), and measured nAb titers
elicited in all three groups (Fig 1E). This assay showed that DSV4 VLPs could induce nAbs
Table 1. Antigenic integrity of EDIIIs on DSV4 VLPs using sandwich ELISA.






1 E103 DENV-1 BC loop (LR) 3.96 14.4 ++++
2 3H5 DENV-2 A strand, BC loop (LR) 0.77 2.8 +
3 70 A strand, LR 0.48 1.75 +
4 106 A strand, LR 0.51 1.85 +
5 104 C strand/C-C’ loop 0.52 1.89 +
6 8A1 DENV-3 N terminus of A strand, FG loop (LR) 1.30 4.72 ++
7 E51 LR 3.90 14.18 ++++
8 E88 DENV-4 BC, DE loops (LR) 0.53 1.92 +
9 E76 DENV-2, -4 N terminus of A strand, C-C’ loop, B, D & G strands 0.51 1.85 +
10 E106 DENV-1, -4 A strand, LR 3.60 13.09 ++++
11 E113 DENV-1, -2, -4 LR 1.20 4.36 ++
12 h-2J20 DENV-1, -3 ? 2.50 9.09 +++
13 E61 DENV-1, -2, -3, -4 A and G strands 0.71 2.58 +
14 E77 A strand, BC loop (LR), and G strand 0.81 2.95 +
15 h-2K2 DENV-1, -2, -3, -4 prM 0.06 0.22 -
16 4G2 FL 0.05 0.18 -
17 h-1M7 0.06 0.22 -
18 h-DVC23.3 0.05 0.18 -
19 3H4 0.05 0.18 -
20 h-1N5 0.05 0.18 -
aS.Nos. 1–14: Anti-EDIII mAbs; S.Nos. 15–20: Non-EDIII mAbs
bmAbs are described in the following references: h-DVC23.3 [16]; h-2K2 [21]; E103, E106 & E113 [29]; 3H5 & 4G2 [49]; 8A1 [50]; E51, E61, E77 [51]; 3H4 & h-2J20
[52]; h-1M7 & h-1N5 [53]; 70, 104 & 106 [54]; E76 & E88 [55].
cS/Co: Signal (ELISA OD)/Cut-off; Cut-off = 0.275 (mean ELISA OD obtained using S antigen with each of the 20 mAbs plus 3x SD).
dReactivity was graded based on values of S/Co:—(<1); + (1.1–3.0); ++ (3.1–5.0); +++(5.1–10); ++++ (>10.1)
?: unknown
https://doi.org/10.1371/journal.pntd.0006191.t001
against all four DENV serotypes in all three murine strains. The nAb titers between C57BL-6
and C3H groups were comparable for DENV-1, -3 and -4, with DENV-2 titers being signifi-
cantly lower in the latter group (p = 0.006). The C3H mice elicited significantly lower nAb
titers to DENV-1 (p = 0.007) and DENV-2 (p = 0.004), but not to DENV-3 and DENV-4, com-
pared to BALB/c mice. DENV serotype-wise nAb titers between the BALB/c and C57BL-6
groups were comparable, with overall titers slightly higher in case of the former strain. All fur-
ther immunogenicity data reported were obtained using the BALB/c strain.
In contrast to the preceding experiment, we immunized next a fresh group of BALB/c mice
with DSV4 VLPs formulated in alhydrogel alone as adjuvant. Antisera from these mice were
pooled and tested in DENV neutralization assay against all four serotypes as depicted in Fig
2A. Comparison of the resultant FNT50 titers against the four DENV serotypes (Fig 2A, lower
Table marked ‘DSV4’) with the corresponding titers obtained in the earlier experiment (Fig
1E) revealed that alhydrogel alone was adequate as an adjuvant for DSV4 in BALB/c mice.
Therefore, all further BALB/c immunizations were performed using alhydrogel as the
adjuvant.
Are the nAb titers elicited by DSV4 serotype-specific? To address this, we created monova-
lent VLPs based on the DSV4 platform, in which the four tandem EDIIIs were all of either
serotype 3 or serotype 4, and mixed these two together into a bivalent formulation (referred to
as DSV2 in Fig 2A, upper table). Antisera from BALB/c mice immunized with DSV2 lacked
any significant neutralizing activity towards DENV-1 and DENV-2, but neutralized DENV-3
and DENV-4 almost as efficiently as did the anti-DSV4 antiserum (Fig 2A, lower Table).
Thus, the EDIII component elicits nAbs specific to the cognate serotype from which it was
derived. To corroborate this, we evaluated the effect of pre-depleting the anti-DSV4 antiserum
of anti-EDIII antibodies of a given serotype on nAb titers specific to the cognate serotype. To
this end, we pre-incubated anti-DSV4 antiserum with specific recombinant EDIII-MBP fusion
proteins immobilized on amylose matrix (S1 Appendix) and then measured the levels of resid-
ual DENV-nAb titers (Fig 2B). Pre-depletion of anti-DSV4 antisera on immobilized EDIII-
3-MBP led to significant abrogation of nAb titers specific to DENV-3 alone (p = 0.028), with-
out appreciable effect on the nAb titers towards the remaining serotypes, as can be seen in Fig
2B (p values for DENV-1, -2 and -4 were>0.999, = 0.485 and>0.999, respectively, between
the MBP and EDIII-3-MBP depleted antisera, by the Mann-Whitney test). On the other hand,
DENV-3 specific nAb titers were essentially unaffected when the pre-depletion was carried
out with immobilized EDIII-2-MBP, which specifically decreased nAb titers against DENV-
2 (Fig 2C). Collectively, the data leads to the conclusion that DSV4 elicits tetravalent sero-
conversion and strongly suggests EDIII-focused antibodies elicited by DSV4 are responsible
for mostly serotype-specific virus neutralization. Further, we also found that the DSV4
VLP-induced tetravalent immune response in BALB/c mice is durable. In an independent
experiment, we could detect significant nAb titers (FNT50 titers of 296, 55, 105 and 33,
respectively, for DENV-1, -2, -3 and -4) at 3 months after the last immunizing dose. The
data on the nAb titers elicited by DSV4 in BALB/c discussed above were obtained using
pooled sera. We were interested to know if all mice in a group responded to DSV4 compara-
bly. To this end, we immunized a fresh set of 8 BALB/c mice with DSV4 and analyzed indi-
vidual sera for FNT50 titers against all four DENVs. This experiment revealed that seven of
eight mice mounted a tetravalent immune response against all four DENVs with the eighth
manifesting trivalent seroconversion (Fig 2D), showing that it is reasonable to use pooled
antisera for nAb determinations.
DENVs manifest intra-serotypic variations, known as genotypes. Genotypes within a given
serotype can have up to 6% nucleotide sequence divergence in the E gene [56]. Could this
affect the pan-DENV neutralizing efficacy of anti-DSV4 antibodies? To address this we
assessed the virus neutralizing efficacy of antibodies elicited by DSV4 VLPs against multiple
genotypes of each of the four DENV serotypes. Fig 2E depicts the DENV-nAb titers elicited by
DSV4 VLPs against a total of 11 genotypes, representing the four DENV serotypes. The data
show that the polyclonal repertoire of antibodies induced by DSV4 VLPs has adequate breadth
of antigenic specificity encompassing multiple genotypes of each of the four DENV serotypes.
Control mice immunized with S VLPs (or PBS) did not elicit discernible nAb titers against any
of the four WHO strains of DENVs. These data are consistent with our observation that the
EDIII sequences of the four specific DENV strains in DSV4 share a high degree of identity
with EDIIIs of several hundred DENVs, corresponding to each of the four cognate serotypes
in the NCBI database (S3 Table).
Fig 2. DSV4 elicits tetravalent seroconversion in BALB/c mice. (A) Virus neutralizing activity of anti-DSV4 antiserum (pooled from 6 mice) against
WHO reference strains of DENV-1 (magenta), DENV-2 (green), DENV-3 (blue) and DENV-4 (black) as a function of serum dilution, determined using
the FACS-based assay. The dashed horizontal line indicates 50% neutralization of virus infectivity. Data points represent mean (n = 6) values; the error
bars represent SD. Tables above the graph indicate neutralizing antibody titers (FNT50) elicited by DSV4 (tetravalent immunogen) and DSV2 (bivalent
immunogen). Mann-Whitney test-derived p values comparing nAb titers elicited by DSV4 in panel A above (alhydrogel alone as adjuvant) and DSV4 in
Fig 1E (alhydrogel + MPLA mixture as adjuvant) against DENV-1 (0.901), -2 (0.710), -3 (0.804) and -4 (0.382) showed no significant differences between
the two adjuvant groups. (B) Virus nAb titers against the same four DENV strains indicated in panel A in anti-DSV4 antiserum post-depletion using
either MBP (solid curves, left panel) or EDIII-3-MBP (dashed curves, right panel). The four DENV serotypes are indicated using the same colors as in
panel A. The table on the top indicates calculated FNT50 titers post MBP (middle row) and EDIII-3-MBP (bottom row) depletion. (C). Similar
experiment as in panel B except that depletion was with either MBP (solid curves) or EDIII-2-MBP (dashed curves), followed by FNT50 titer
determination against DENV-2 (green) and DENV-3 (blue). In panels ‘B’ and ‘C’, nAb titers post-depletion with the MBP carrier or specific EDIII-MBP
fusion protein are boxed to highlight specific depletion; nd: not done. (D) Determination of FNT50 titers against DENV-1, DENV-2, DENV-3 and
DENV-4 in individual (1–8) and pooled (P, n = 8) antisera from BALB/c mice immunized with DSV4 VLPs. Pooled antisera from a group of BALB/c
mice (n = 6) immunized with S VLPs served as the control. DENVs used and the colors to indicate the different serotypes are the same as in panel A. (E)
Pooled sera from BALB/c mice (n = 6 per group) immunized with DSV4 VLPs and control mice, immunized with 1x PBS, were analyzed for FNT50 titers
against various genotypes corresponding to each of the four DENV serotypes. DENV-1 (magenta) genotypes analyzed were West-Pac 74 (1a), UNC1036
(1b) and UNC1017 (1c); DENV-2 (green) genotypes were S-16803 (2a), IQT2133 (2b) and UNC2037 (2c); DENV-3 (blue) genotypes were CH53489
(3a), UNC3043 (3b) and UNC3001 (3c); and DENV-4 (black) genotypes were TVP360 (4a) and UNC4019 (4b). Data are average of two replicate
determinations with error bars shown. Control mice sera did not manifest discernible FNT50 titers (<10) even at the lowest serum dilution tested against
any of the DENVs.
https://doi.org/10.1371/journal.pntd.0006191.g002
DSV4 VLP-induced antibodies enhance DENV infection in K562 cells but
not in AG129 mice
Having demonstrated that DSV4 elicits tetravalent seroconversion, we were interested to
determine if the anti-DSV4 antibodies could mediate enhancement of DENV infection. We
evaluated this in vitro by measuring the degree of infection of FcγR-containing K562 cells
which are not susceptible to DENV infection in the absence of anti-DENV antibodies. The
data shown in Fig 3A reveal that enhancement did occur as evidenced by the characteristic
‘bell-shaped’ curves defining the degree of DENV infection as a function of anti-DSV4 antise-
rum dilution. Peak enhancement (~30% infection) occurred at antiserum dilutions ranging
from ~100 fold (for DENV-2) to ~1000 fold (for DENV-1). The question we addressed next
was: would this enhancement seen in vitro be evident in vivo? To address this, we used the
interferon (IFN) α/β and γ receptor-lacking AG129 mouse-based ADE model [57]. Groups of
AG129 mice were subjected to passive transfer of normal mouse serum (NMS, from un-
Fig 3. Evaluation of enhancement by antibodies elicited by DSV4 VLPs in vitro and in vivo. (A) DENV-1
(magenta), DENV-2 (green), DENV-3 (blue) and DENV-4 (black) were pre-incubated with serial three-fold dilutions
of anti-DSV4 antiserum followed by FACS determination of infection of K562 cells in culture. (B) AG129 mice
received neat NMS (n = 6), anti-DSV4 antiserum, αDSV4 (n = 9) or anti-DENV-2 antiserum, αDENV-2 (n = 4) on
day -1. An aliquot of serum was collected from the AG129 mice just before sub-lethal challenge with DENV-2 S221 on
day 0 for determination of pre-challenge FNT50 titers indicated in parenthesis along the horizontal axis. On day 3,
serum viremia was determined by real time analysis. (C) Mice in panel ‘B’ were monitored daily for survival. Pre-
challenge FNT50 titers are indicated in parenthesis adjacent to the groups. The difference in survival of the NMS and
αDSV4 was not significant (p>0.999), while those between NMS and αDENV-2 (p = 0.016) and αDSV4 and αDENV-2
(p = 0.004) groups were significant, based on the Mantel-Cox test. (D) Experimental groups (n = 5) were similar to
those in panel C, with multiple dilutions of αDSV4 and αDENV-2 antisera (pre-challenge FNT50 titers indicated in
parenthesis) being used for passive transfer on day -1. A control group received mAb 4G2. All were challenged as
before on day 0, and monitored for survival. Survival curves for different groups (panels C and D) at the 100% mark
have been slightly displaced to make them visible. The anti-DSV4 antisera used in the in vitro and in vivo experiments
were from different immunizations. The difference in survival of the NMS and αDSV4 was not significant (p>0.999),
while the survival rates of NMS group (p = 0.0002), αDSV4, all dilution groups (p = 0.002), αDENV-2, 45–84 group
(p = 0.014), and αDENV-2, 150–160 group (p = 0.004), compared to that of the 4G2 group, were significantly higher,
based on the Mantel-Cox test.
https://doi.org/10.1371/journal.pntd.0006191.g003
immunized BALB/c mice), anti-DSV4 antiserum (αDSV4, from DSV4 VLP-immunized
BALB/c mice) or anti-DENV-2 antiserum (αDENV-2, from DENV-2 immunized BALB/c
mice), followed by a previously optimized sub-lethal challenge dose of DENV-2 S221 (5x103
FIU/mouse). Experimentally determined pre-challenge DENV-2 nAb titers in the NMS,
αDSV4 and the αDENV-2 passive transfer groups were, respectively, <10, 57 and 33 (Fig 3B).
Evaluation of DENV genomic RNA levels by real time analysis on day three post-challenge
showed relatively higher viremia in the NMS group. Mice in the αDENV-2 group displayed
statistically non-significant (p = 0.257) reduction in post-challenge viremia. However, anti-
DSV4 antiserum could effectively block DENV-2 S221 replication, in the αDSV4 group, as evi-
denced by a ~1 log reduction in viremia, which was statistically significant (p = 0.0004). The
day 3 post-challenge time point to assess viremia was chosen based on prior optimization
experiments. Interestingly, mice in both NMS- and αDSV4 groups manifested 100% survival
while 75% mice in the αDENV-2 group succumbed to the sub-lethal challenge very early (Fig
3C). Given that pre-challenge nAb titer was higher in the αDENV-2 group (33) than in the
NMS group (<10), it may be inferred that enhancing antibodies in the anti-DENV-2 antise-
rum had caused a sub-lethal challenge to become lethal. Interestingly, anti-DSV4 antiserum
(pre-challenge nAb titre = 57) not only suppressed viremia significantly compared to NMS,
but also did not augment the sub-lethal challenge into a lethal one. This leads to the conclusion
that unlike live DENV-2-induced antibodies, the antibodies elicited by DSV4 do not cause
ADE in vivo. Interestingly, the lack of ADE by anti-DSV4 antibodies in vivo (AG129) was not
predicted by the observation of ADE in vitro (K562).
Anti-DSV4 antibodies do not possess discernible in vivo ADE potential
One possible reason for the inconsistency in outcomes between the in vitro and in vivo ADE
experiments could be that in the former we used serially diluted anti-DSV4 antisera while in
the latter we used neat antisera which at best undergo 10–12 fold dilution upon passive transfer
into AG129 mice. In other words, would mice in the αDSV4 group experience ADE upon sub-
lethal DENV-2 S221 challenge, if the pre-challenge titers were lower? To address this, we used
different starting dilutions of passively transferred antiserum to result in a range of lower pre-
challenge nAb titers (<10 to 34) in the αDSV4 group. The data are summarized in Fig 3D. As
expected, mice which received NMS, survived the sub-lethal challenge. In contrast, all the mice
which received 4G2 mAb (at a concentration shown to completely neutralize the sub-lethal
challenge virus dose in vitro) succumbed on post-challenge day 5 (p = 0.0002). This is consis-
tent with the reported behavior of this mAb [48]. On the other hand, it is remarkable that the
introduction of anti-DSV4 antiserum at dilutions resulting in the near total lack of pre-chal-
lenge DENV-2 nAb titers (<10, corresponding to final dilution of 80-fold) did not predispose
AG129 mice to any discernible mortality, compared to the 4G2 group (p = 0.0027). In striking
contrast, relatively higher levels of pre-challenge DENV-2 nAb titers (18–44, corresponding to
a final dilution of 100-fold) resulting from passive transfer of anti-DENV-2 antiserum was
associated with very significant mortality (p = 0.0014), as seen in the previous experiment.
This could largely, but not completely, be counteracted by increasing the pre-challenge
DENV-2 nAb titers in the anti-DENV-2 antiserum group to45 (final dilution of 20- to
50-fold). Thus the ADE manifested upon progressive dilution of DENV-2 nAb titers in anti-
DENV-2 antiserum (in the range of 20- to 100-fold) is not discernible upon progressive dilu-
tion of nAb titers in anti-DSV4 antiserum (in the range of 10- to 80-fold). These data clearly
demonstrate the lack of in vivo ADE potential of DSV4 VLP-induced antibodies, in contrast to
the high ADE potential of DENV-2-induced antibodies and strongly suggest that in vitro ADE
assay may not reflect in vivo ADE potential accurately.
DENV-2 S221 complexed to anti-DSV4 antibodies does not promote
AG129 mortality
The lack of ADE in vivo by anti-DSV4 antibodies was corroborated using an alternate strategy
[48]. In this approach, we first generated, in vitro, completely neutralized immune complexes
(ICs) of DENV-2 S221 by incubating a sub-lethal dose with adequate amounts of mAb 4G2,
homotypic anti-DENV-2 S221 antiserum or anti-DSV4 antiserum. We also generated par-
tially-neutralized ICs wherein DENV-2 S221 was 30% neutralized, using an appropriate
dilution of anti-DSV4 antiserum [αDSV4 (30%)]. This was done to simulate lower nAb con-
centrations implicated in causing ADE. All four different kinds of ICs were injected separately
into groups (n = 6) of AG129 mice and compared with a fifth group (control) which received
an equivalent dose of free DENV-2 S221 (not complexed to any anti-dengue antibody, pre-
incubated with NMS). Unlike in the passive transfer experiments, we monitored these mice
for a longer duration (up to 45 days) to examine if the lack of enhancement seen above with
anti-DSV4 antibodies (Fig 3, panels C & D) would be overcome by increased DENV-2 S221
replication at later times. This experiment was done twice and the data from one of these are
depicted in Fig 4A. Consistent with conclusions from the data in Fig 3D, as well as earlier
reported studies [48], injection of the mAb 4G2-ICs resulted in 100% mortality in 5 days. In
contrast, αDSV4 ICs did not result in any mortality. Remarkably, the partially neutralized ICs
[αDSV4 (30%)] also did not result in any significant mortality for the entire duration of the
experiment. The survival of control group which received free DENV-2 S221 (pre-incubated
with NMS) began to decline after ~2 weeks, with all mice succumbing by ~4 weeks, despite
homotypic FNT50 titers of ~3,000–4,000 in the preceding 24–48 hours. Clearly, these high nAb
titers elicited by the virus could not preclude ADE. Consistent with this notion, the mortality
of the group administered with fully neutralized ICs made using homotypic anti-DENV-2
antiserum (αDENV-2 group) was high and equivalent to those that received mAb 4G2-ICs. In
both these instances, the virtual lack of any discernible protection against sub-lethal challenge,
Fig 4. Lack of ADE by anti-DSV4 antibodies correlates with protective efficacy in AG129 mice. (A) Groups (n = 6) of AG129 mice were challenged
with sub-lethal dose of DENV-2 S221 pre-incubated with normal mouse serum (NMS) or in vitro-generated ICs of the same sub-lethal dose of DENV-2
using either sub-neutralizing amounts of anti-DSV4 antiserum [αDSV4 (30%)], or fully neutralizing amounts of anti-DSV4 antiserum [αDSV4 (100%)],
anti-DENV-2 antiserum [αDENV-2 (100%)] or mAb 4G2 [4G2 (100%)], and monitored for survival. Survival curves for different groups at the 100%
mark have been slightly displaced to make them visible. Survival rates of αDSV4 (30%) IC group (p = 0.0009) and αDSV4 (100%) IC group (p = 0.0009),
compared to that of the 4G2 (100%) group was significant, based on the Log-Rank (Mantel-Cox) test; with respect to the NMS group (challenged with
free DENV-2 S221) also, survival was significantly higher for αDSV4 (30%) group (p = 0.006) and the αDSV4 (100%) group (p = 0.0006). (B) Groups of
AG129 mice (n = 3) were challenged as described in panel A with the exception that the αDSV4 (30%) IC group was replaced with an untreated group to
serve as the negative control (NC). Three days post-inoculation mice were euthanized, small intestines dissected out after perfusion and homogenized.
Clarified homogenates were used for the determination of TNF-α using a commercial ELISA kit with purified recombinant murine TNF-α as the
reference. (C) The same experiment as in panel B, except that the clarified homogenates were used for IL-6 determination using a commercial ELISA kit
with purified recombinant murine IL-6 as the reference. Data shown in panels ‘B’ and ‘C’ are mean values (n = 3) with the bars denoting standard
deviation. Unpaired t test was used to derive the p values shown in panels B and C.
https://doi.org/10.1371/journal.pntd.0006191.g004
despite the DENV-2 S221 in the ICs being 100% neutralized by mAb 4G2 and the homotypic
anti-DENV-2 antiserum, reflects the enormous ADE potential of these antibodies. In contrast,
such ADE is not evident in case of the ICs generated using anti-DSV4 antibodies, even at sub-
neutralizing concentrations, typified by the αDSV4 (30%) group.
It has been documented that ADE in AG129 mice caused by ICs made of mAb 4G2 and
DENV-2 S221 is associated with increased vascular permeability and the production of TNF-α
and IL-6, especially in the small intestines [48]. We examined these two pro-inflammatory
cytokine markers of small intestinal pathology in the various IC-inoculation groups (n = 3, set
up in parallel) described in the previous experiment. Data on the levels of these two cytokines
in the small intestines of AG129 mice, three days after IC inoculation are depicted in Fig 4
(panels B and C). Both TNF-α and IL-6 levels were elevated upon DENV-2 S221 challenge
(NMS group) compared to un-challenged controls (NC group). This was further elevated in
mice which received the mAb 4G2-containing ICs. A remarkable spurt in the levels of these
cytokines was evident in the small intestines of mice inoculated with ICs generated using anti-
DENV-2 S221 antisera instead (αDENV-2 group). The mice in these two latter groups suc-
cumbed by post-IC inoculation day 5. In striking contrast, TNF-α and IL-6 levels in the small
intestines of mice in the αDSV4 IC group were reduced below those in the NMS group (chal-
lenged with free DENV-2 S221). It is noteworthy that these mice did not display any mortality
(Fig 4A). Collectively, the early cytokine data are quite consistent with the survival data in the
in vivo ADE experiments. Taken together, these findings suggested that the antibodies elicited
by DSV4 VLPs are qualitatively superior in the context of affording a prolonged survival
advantage to sub-lethal DENV-2 challenge in these experiments. The data thus far provide evi-
dence that antibodies elicited by DSV4 not only do not mediate ADE, but also apparently con-
fer protection. These data suggest that it is not just nAb titers, but nAbs devoid of enhancing
potential, which offer a better correlate of protection.
Anti-DSV4 antibodies afford significant protection against lethal DENV-4
challenge in AG129 mice
The experiments described above demonstrated that passively transferred anti-DSV4 antibod-
ies suppressed DENV-2 viremia and a sub-lethal DENV-2 infection from turning lethal in
AG129 mice (Fig 3, panels B-D and Fig 4A). While these data indicate protection against ADE,
they do not constitute evidence of protection against a lethal infection. DSV4 VLPs tended to
elicit relatively lower nAb titers against DENV-4, compared to the remaining serotypes, in
BALB/c mice (Figs 1E and 2A). Would such titers be adequate to protect against lethal DENV-
4 challenge? To address this, we used DENV-4, 703–4, a recently reported challenge DENV
strain [58]. We performed an initial dose escalation study to determine the lethal dose of
DENV-4, 703–4. As done earlier, immune serum from DSV4 VLP-immunized BALB/c mice
was passively transferred into AG129 mice (αDSV4 group, pre-challenge DENV-4 FNT50 =
143), which were then challenged with a lethal dose of DENV-4, strain 703–4. For comparison,
we also challenged groups of AG129 mice which had received either NMS or anti-DENV-4
antiserum (αDENV-4 groups, at two different dilutions, 1:3 and 1:10) through passive transfer.
On day 3 post-challenge, viremia was evaluated by real time analysis of DENV-4 genomic
RNA (Fig 5A). The data showed that the αDSV4 group manifested statistically significant
reduction in DENV-4 viremia compared to the NMS control group (p = 0.028). A comparable
reduction in viremia was also evident in the group passively transferred with ten-fold diluted
anti-DENV-4 antiserum (pre-challenge DENV-4 FNT50 = 45). This was suppressed even fur-
ther in the group that received three-fold diluted anti-DENV-4 antiserum (pre-challenge
DENV-4 FNT50 = 139). Despite this, mortality in these two latter groups was 100% and 50%,
respectively (Fig 5B). Remarkably, survival rate was 75% for the mice that received anti-DSV4
antiserum (p = 0.027). It is noteworthy that the αDSV4 group and the αDENV-4 1:3 group
had similar pre-challenge titers (FNT50 ~140), with viremia being lower in the latter compared
to the former group. However, this lowered viremia was statistically non-significant (p =
0.057). Clearly, high nAb titers and lower viremia in the αDENV-4 1:3 group did not correlate
with better survival against lethal challenge. Once again, the data from these experiments
strengthen the notion that antibodies elicited by DSV4 VLPs are qualitatively superior, in
terms of protective efficacy, compared to antibodies elicited by live DENV-4 infection.
Macaque-induced anti-DSV4 nAbs manifest negligible ADE potential in
the AG129 mouse model
We also evaluated the immunogenicity of DSV4 VLPs in macaques, using two adjuvants: alhy-
drogel and alhydrogel + MPLA. Individual sera were analyzed by indirect ELISA using the
recombinant monovalent EDIII proteins, corresponding to the four DENV serotypes, as well
as recombinant HBV S antigen, as the coating antigens (S4 Fig, panel A). Fig 6A depicts the
ELISA results (as geometric mean titers, GMT), using macaque sera drawn at 2 weeks after the
last immunization. In contrast to mice, we observed that the dual adjuvant formulation medi-
ated an overall augmentation of the immunogenicity of DSV4, compared to the alhydrogel
only formulation. The IgG titers against each of the five coating antigens were approximately
an order of magnitude higher when immunization was with DSV4 formulated in alhydrogel
+ MPLA as compared to that formulated in alhydrogel alone. This was reflected in the DENV
nAb titers as well, shown in Fig 6B. As seen with control murine antisera, control macaque
antisera obtained from PBS-immunized animals did not manifest any detectable DENV-spe-
cific nAb titers. Determination of nAb titers in pooled macaque anti-DSV4 antisera following
depletion of EDIII-specific antibodies revealed varying degrees of cross-reactivity among the
DENV serotypes (S4 Table). Analysis of nAb titers in individual macaques revealed that while
5 of 6 macaques manifested seroconversion to at least three serotypes when immunized with
DSV4 formulated in alhydrogel, all 6 macaques immunized with DSV4 in alhydrogel + MPLA
seroconverted against at least three serotypes (S4 Fig, panel B).
Fig 5. Passively transferred anti-DSV4 BALB/c antiserum suppresses viremia and confers protection to AG129
mice against lethal DENV-4 challenge. (A) Groups (n = 4) of AG129 mice received NMS, anti-DSV4 antiserum (α-
DSV4), or anti-DENV-4 antiserum (αDENV-4) at 2 dilutions (to result in two different pre-challenge nAb titers) on
day -1. Pre-challenge FNT50 titers are shown in parenthesis below. On day 0 the mice were challenged with a lethal
dose of DENV-4 703–4 virus. Serum viremia was determined on day 3. The difference in viremia between the NMS
and αDSV4 groups (p = 0.028), NMS and αDENV-4, 1:3 dilution group (p = 0.028), and αDENV-4, 1:10 dilution
group (p = 0.028) were significant (Mann-Whitney test). (B) Mice in ‘A’ were monitored for survival. The difference in
survival between NMS and αDSV4 groups (p = 0.027), αDSV4 and αDENV-4, 1:10 dilution group (p = 0.036) were
significant (Mantel-Cox test).
https://doi.org/10.1371/journal.pntd.0006191.g005
Finally, we also examined the potential of the macaque-raised anti-DSV4 antiserum to
enhance infection in the AG129/sub-lethal DENV-2 S221 challenge model. For comparison,
we also performed passive transfer with an antiserum raised in macaques immunized with an
‘in house’ tetravalent mixture of inactivated DENVs (TviDV). Each of these two macaque anti-
sera pools was passively transferred into AG129 mice at three different dilutions as indicated
(Fig 6C). At 24 hours post-passive transfer, the mice were challenged with the sub-lethal dose
of DENV-2 S221. The TviDV antiserum, at all three dilutions tested, sensitized the AG129
mice to DENV-2 S221 challenge, based on several indicators of morbidity (Fig 6C, upper three
panels). In striking contrast, anti-DSV4 antiserum did not sensitize the AG129 mice to viral
challenge at all three dilutions (Fig 6C, lower three panels). It is interesting to note that at com-
parable pre-challenge DENV-2 nAb titers anti-DSV4 antiserum and anti-TviDV antiserum
Fig 6. Evaluation of DSV4 in macaques. (A) Serum IgG titers were determined in macaques (n = 6) which had been
immunized with DSV4 formulated either in alhydrogel alone (Alhydrogel) or in alhydrogel with MPLA (Alhydrogel
+MPLA) by indirect ELISA, using purified recombinant EDIII-1 (magenta), EDIII-2 (green), EDIII-3 (blue), EDIII-4
(black) or S (grey) protein as the coating antigen. ELISA titers (GMTs) obtained using the double adjuvant
formulation, were significantly higher than those obtained using the single adjuvant formulation, for each of the five
coating antigens. Differences in ELISA GMTs between the two adjuvant groups for EDIII-1, EDIII-2, EDIII-3, EDIII-4
and S coating antigens were significant, with p values of 0.002, 0.002, 0.002, 0.008 and 0.002, respectively, using the
Mann-Whitney test. (B) Neutralizing antibody titers (FNT50) against WHO reference strains of DENV-1 (magenta),
DENV-2 (green), DENV-3 (blue) and DENV-4 (black) in macaque immune sera from the two adjuvant groups in
panel A were determined using the FACS-based assay. Differences in neutralizing GMTs between the two adjuvant
groups were significant for DENV-1 (p = 0.004), DENV-2 (p = 0.015) and DENV-3 (p = 0.002), but not DENV-4
(p = 0.225), by the Mann-Whitney test. In both panels ‘A’ and ‘B’, data shown are geometric mean values (n = 6); error
bars denote SD. (C) ADE potential of macaque immune sera was analyzed in AG129 mice. Data show the morbidity
scores of AG129 mice (n = 5; symbols denote individual mice, monitored over 10 days) passively transferred with
pooled macaque anti-TviDV antiserum (top panels) or macaque anti-DSV4 antiserum (bottom panels) at three
dilutions, as indicated and challenged a day later with a sub-lethal dose of DENV-2 S221. Pre-challenge FNT50 titres
are indicated in parenthesis adjacent to the corresponding dilutions used. Morbidity scores were as follows: 0.5, mild
ruffled fur; 1, ruffled fur; 1.5, loose stools, eyes compromised; 2, lethargy; 2.5, limited mobility from stimulation,
hunching; 3, Not moving, or>20% initial weight loss; 4, moribund. Mice were euthanized when score was 3 or higher.
https://doi.org/10.1371/journal.pntd.0006191.g006
manifested contrasting outcomes in this experiment, corroborating the qualitative superiority
of antibodies in the former compared to the latter antiserum. The observed lack of discernible
ADE by macaque-raised anti-DSV4 antibodies, in the AG129 model, is consistent with the
lack of infection enhancement by BALB/c-raised anti-DSV4 antibodies, in the same ADE
model, and lends strength to the conclusion that DSV4 is not associated with the induction of
disease-enhancing antibodies. This is a vital and desirable feature of the DSV4 VLP candidate
as it can potentially circumvent or minimize the possibility of ADE in vaccine recipients.
Discussion
The search for an ideal dengue vaccine is far from over as the recently launched live attenuated
dengue vaccine appears to be linked to possible ADE in young children. To make a dengue
vaccine safe it is necessary to eliminate or minimize the risk of potential ADE by avoiding epi-
topes implicated in the induction of enhancing antibodies. Several recent studies have led to
the recognition that DENVs subvert a major part of the human antibody response towards
generating weakly neutralizing, cross-reactive enhancing antibodies [15–17]. This should no
doubt be true for live attenuated dengue vaccine virus strains as well. We chose to focus on
EDIII as it would not only enable the elimination of prM and other parts of E implicated in
ADE, it would also help focus the immune response to a functionally relevant epitope capable
of eliciting potent DENV-nAbs. To compensate for the apparent non-immunodominance of
EDIII, we displayed it on HBV S antigen-based VLP platform, and created mosaic VLPs dis-
playing EDIIIs of all four DENV serotypes linked in tandem in a head-to-tail array, akin to the
RTS,S vaccine for malaria [43, 44].
Though the AG129 mouse is susceptible to DENV infection and can manifest ADE, we
opted to assess the immunogenicity of DSV4 in the BALB/c mouse. This is because the latter
being immunocompetent is likely to reflect the immunogenicity of DSV4 more appropriately.
Further, subunit vaccines tend to be less immunogenic in the AG129 mouse due to its genetic
defect in the innate immune signaling pathway [59]. DSV4 formulated in alhydrogel adjuvant
was immunogenic in BALB/c mice (as well as two other mouse strains), eliciting tetravalent
seroconversion. Consistent with its design, DSV4 elicited antibodies to EDIIIs of all four
DENV serotypes and to the HBV S antigen. Importantly, DSV4-elicited antibodies could neu-
tralize the infectivity of all four DENVs. The nAb titers ranged from ~360 (DENV-4) to ~970
(DENV-3). These nAb titers are not insignificant given that it is conventionally accepted that
titers >10 are protective. In this context, a longitudinal cohort study published recently found
an inverse relationship between the probability of symptomatic DENV infection and serum
nAb titers [60]. Further, the virus-neutralizing activity of the DSV4-induced antibodies
spanned multiple genotypes. This breadth of virus neutralization across genotypes within each
serotype is apparently the outcome of the polyclonal antibody response which is able to over-
come the intra-serotypic variation among the genotypes. This also attests to the utility of EDIII
as a vaccine immunogen whose serotype-specificity is conserved across genotypes. Though we
tested only a total of 11 genotypes (representing the four DENV serotypes), it is noteworthy
that the EDIII sequence of each DENV serotype represented in DSV4 shares88% identity
with the EDIII of the top 500 dengue sequences of the cognate serotype in the NCBI database
(S3 Table).
Would nAbs elicited by DSV4 VLPs mediate ADE? It is known that even potent nAbs, if
sufficiently diluted, can cause ADE in vitro. We could see evidence of homotypic enhancement
in K562 cells using serially diluted anti-DSV4 antiserum. However, it is becoming increasingly
apparent that in vitro ADE data obtained using FcγR-containing cells such as K-562 and THP-
1, do not reflect in vivo ADE potential of serotype-specific nAbs. For example, the type-specific
DENV-2 mAb 3H5 which at low doses can cause ADE in THP-1 cells did not enhance DENV-
2 infection of AG129 mice [48]. Similarly, though polyclonal dengue-immune macaque serum
enhanced infection of K562 cells by zika virus (ZIKV), a related flavivirus, ZIKV-challenged
dengue-immune macaques did not experience infection enhancement [61]. Thus, rather than
in vitro ADE data obtained using K562 cells, we hold that it is more appropriate to assess in
vivo ADE potential using the AG129 model [57]. Nonetheless, the data need to be interpreted
with caution as there have not been adequate studies to determine the correlation between in
vitro ADE using a biologically relevant concentration of dengue immune sera (i.e., undiluted)
with disease outcome in humans experiencing a post-primary dengue infection.
Remarkably, we found that anti-DSV4 antiserum dilutions high enough to result in virtu-
ally undetectable pre-challenge nAb titers did not cause ADE in vivo. This conclusion was fur-
ther fortified by showing that sub-lethal doses of DENV-2 S221 neutralized in vitro, either
partially or completely, with anti-DSV4 antiserum did not cause significant mortality when
injected into AG129. This is consistent with a recent report which showed that partially neu-
tralized DENV-2 ICs generated using EDIII-2-specific mAb 3H5 did not manifest significant
ADE in AG129 mice in contrast to completely neutralized DENV-2 ICs generated using mAbs
4G2 and 6B6C-1, which target epitopes outside EDIII [48].
Interestingly, antisera against DENV-2 (whether in the passive transfer experiment in Fig
3D or in the IC inoculation experiment shown in Fig 4A) augmented a sub-lethal DENV-2
infection, resulting in ADE. This is intriguing because it represents ADE by homotypic anti-
bodies. While this requires further study, it must be pointed out that DENV is potentially capa-
ble of eliciting large amounts of cross-reactive antibodies [15–17], presumably targeting
epitopes outside EDIII as well as anti-prM antibodies, which can mediate ADE. Collectively,
these data lead to the conclusion that anti-EDIII antibodies may lack ADE potential in vivo
even at low concentrations. This represents an inherent safety attribute of the DSV4 vaccine
candidate.
Though the AG129 mouse represents an immune-compromised model, its limitation in
assessing DSV4 vaccine efficacy was somewhat overcome in that DSV4-induced antibodies
were raised in immunocompetent BALB/c mice. Support for the notion that anti-DSV4 VLP-
induced antibodies confer protection against potentially lethal DENV infection emanates from
the following: (i) passive transfer of antibodies elicited by DSV4 VLPs significantly suppressed
viremia upon sub-lethal challenge of AG129 mice with DENV-2 S221 (Fig 3B); (ii) AG129
mice challenged with a sub-lethal dose of DENV-2 S221 (‘NMS’ group) which show no signs
of mortality for 2 weeks, succumb completely by 4 weeks (Fig 4A). This means that the sub-
lethal dose over time has become lethal due to virus replication. High survival rates of AG129
mice inoculated with the same sub-lethal dose of DENV-2 S221 in the form of ICs (either par-
tially or fully neutralized) generated in vitro with anti-DSV4 VLP antiserum well beyond 4
weeks, when all mice in the ‘NMS’ group have been killed, is noteworthy; (iii) anti-DSV4 anti-
bodies also suppressed viremia in AG129 mice challenged with a lethal dose of DENV-4 strain
703–4 (Fig 5A). In addition, these anti-DSV4 antibodies conferred a significant level of protec-
tive efficacy against such lethal challenge (Fig 5B). DSV4 was also immunogenic in macaques,
while requiring an additional adjuvant, eliciting nAbs to all four DENV serotypes, which did
not manifest any in vivo ADE, using the AG129/sub-lethal DENV-2 S221 challenge model. We
did not attempt to evaluate the protective efficacy or ADE potential of DSV4 in macaques at
this stage due to ethical issues, biocontainment requirements and high cost.
Our data provide proof-of-concept supporting the in vivo efficacy of DSV4 and lack of
ADE. These studies need to be extended to all serotypes. DSV4 is produced in yeast, which has
a high expression potential. It elicits nAbs, with negligible ADE potential, against the function-
ally relevant serotype-specific EDIIIs. DSV4 may possibly help in circumventing potential
ADE of ZIKV infection [62]. Indeed, recent work has shown that antibodies to DENV EDIII do
not enhance ZIKV infection [63]. DSV4 is based on a VLP platform that is inherently highly
immunogenic, with the S antigen providing T-cell help. In this context, it is relevant to note that
prior HBV immunity in vaccine recipients may be beneficial, based on studies of the RTS,S
malaria vaccine which found HBV seropositive recipients manifested earlier and efficient sero-
conversion to malarial antigen [64]. The unique four-in-one antigen design facilitates the expres-
sion and purification of a single tetravalent immunogen, as opposed to making four monovalent
vaccines. These data support the promise of DSV4 as an alternate dengue vaccine candidate.
Supporting information
S1 Appendix. Supplementary materials and methods.
(DOCX)
S1 Fig. Design and expression of DSV4. (A) DS-pPICZA plasmid with DS gene cloned
between the alcohol oxidase 1 (AOX1) promoter and the AOX1 transcription terminator (T).
The EDIII-1, EDIII-2, EDIII-3, EDIII-4 and S encoding regions of the DS gene which are in
frame with each other are indicated by the magenta, green, blue, black and grey boxes, respec-
tively. This 3.4 kb DS expression cassette (indicated by the white star) is flanked by Bgl II and
Bam HI sites. (B) 4S-pAO815 plasmid carrying a 7.8 kb insert (indicated by the black star sym-
bol) flanked by Bgl II and Bam HI sites. The 7.8 kb insert carries 4 copies of the S antigen ex-
pression cassette in a tandem head-to-tail array. (C) DSV4-pAO815 plasmid generated after
insertion of 3.4 Kb DS gene expression cassette into the Bam HI site of the 4S-pAO815 plasmid.
The DSV4 part (indicated by the white and black star symbols) of this construct is represented
by the 11.2 Kb sequence flanked by Bgl II and Bam HI sites. Maps are not drawn to scale. (D)
Agarose gel analysis of the three plasmids in ‘A’ (lane 2), ‘B’ (lane 3) and ‘C’ (lane 4), following
double digestion with Bgl II and Bam HI. Fragment lengths of DS (3.4 kb), S (7.8 kb) and DSV4
(11.2 kb) expression cassettes are indicated by white, black, and combination of white and black
stars, respectively. (E) Whole cell lysates (lanes 1 & 4), supernatants (lanes 2 & 5) and solubilized
pellets (lanes 3 & 6) of un-induced (lanes 1–3) and induced (lanes 4–6) cells obtained after lysis
in native buffer were analyzed for the presence of DSV4 by silver staining. Low molecular weight
protein markers were analyzed in lane ‘M’. Their sizes (kDa) are shown on the left. Positions of
DS, S dimer and S are indicated on the right. (F) Same samples as in ‘E’ analyzed in a Western
blot with HBsAg specific antibody. Pre-stained protein size markers were analyzed in lane ‘M’.
Their sizes (kDa) are shown on the left. Positions of DS, S dimer and S are indicated on the
right. (G) Time-dependent expression-optimization of DSV4 induced at fixed methanol con-
centration (2%). Aliquots of 1ml induced culture were collected at indicated times and the
amount of DSV4 was quantified by ELISA with HBsAg specific antibody. (H) Methanol-depen-
dent expression-optimization of DSV4 induced for fixed duration (72 hours). DSV4 was quanti-
fied as in ‘G’, following induction using methanol at the indicated concentrations.
(TIF)
S2 Fig. Purification and initial characterization of DSV4. (A) Purification profile of DSV4
using hydrophobic interaction chromatography on phenyl-600M. Blue and black lines have
their corresponding y-axis in blue and black color, respectively. The solid blue line represents
the elution profile monitored by absorbance at 280 nm. Black dashed and dotted lines repre-
sent pH and urea concentration, respectively. Quality of protein eluted in each of the four
peaks (1, 2, 3 and 4) was analyzed by silver stained SDS-PAGE (inset). (B) DSV4 fractions
from peaks 3 and 4 (panel A) were pooled and analyzed by silver stain (lane 1), Western blots
with HBV S specific antibody (lane 2) and in-house dengue specific antibody (lane 3). (C)
Three batches (I, II and III) of purified and dialyzed DSV4 at three different concentrations
(lane 1: 1.2 μg; lane 2: 0.6 μg and lane 3: 0.3 μg) were analyzed in Western blots using anti-
HBV S antigen-specific mAb. Positions of DS, S dimer and S (in panel A inset, panels B and C)
are indicated on the right by the upper, middle and lower arrows, respectively. Protein markers
were run in lanes ‘M’; their sizes (in kDa) are indicated on the left of inset in panel A and panel
B. Pre-stained protein markers were run in lane M of panel C; their sizes (in kDa) are indicated
on the left of the batch I panel. Band intensities in the blots were quantified by densitometric
scanning. Ratio of DS/S was calculated for each of the three loads of all the batches to deter-
mine the average DS/S ratio of each DSV4 batch (Table adjacent to panel ‘C’).
(TIF)
S3 Fig. Evaluation of consistency in DSV4 production and its stability to storage under dif-
ferent conditions. (A) Three separate batches of DSV4 (I, II, III) were analyzed for consistency
in yield, VLP size (by DLS) and purity (by densitometry). (B) Silver-stained SDS-PAGE of the
three batches of DSV4. Protein markers were run in lanes ‘M’ and their sizes (in kDa) are indi-
cated on the left of the first gel image (with the marker positions indicated by corresponding
dots to the left of the second and third gel images). The positions of DS, S and S dimer are indi-
cated by the upper, lower and middle arrows, respectively, to the right of the third gel image. (C)
Sandwich ELISA reactivity of the three batches of DSV4 with DENV-1 (magenta), DENV-2
(green), DENV-3 (blue) and DENV-4 (black) -specific EDIII mAbs. The data shown are average
(n = 2) ELISA absorbance (O.D.) values. (D) Schematic representation of the sandwich ELISA
format used with monoclonal antibody specific to EDIII (EDIII mAb) to capture and mAb spe-
cific to S (anti-HBV S-HRPO) to reveal the captured antigen. (E) Silver stained gels of three
DSV4 batches (I, II and III) stored at 4˚C for 1, 2, 3 and 6 months. Each batch was run in tripli-
cates. The positions of DS, S and S dimer are indicated by the upper, lower and middle arrows,
respectively, on the right side of the ‘6th month’ panel. Molecular weight markers were run in
lanes ‘M’; their sizes (in kDa) are indicated on the left of each panel. (F) Silver stained gel of
batch I stored at 25˚C (lane 1), -20˚C (lane 2), -80˚C (lane 3) and in liquid nitrogen (lane 4) for
a month. Further aliquots of DSV4 were stored at 25˚C for 1h (lanes 5, 10), 2h (lanes 6, 11), 4h
(lanes 7, 11), 8h (lanes 8, 13) and 24h (lanes 9, 14). Samples were centrifuged and supernatant
(lane 5–9) and pellet (lane 10–14) fractions were separated and analyzed. Storage of DSV4 at
25˚C was further extended with aliquots collected on days 3 (lane 15) and 5 (lane 16), and the
pellets after centrifugation were analyzed on silver-stained SDS-PAGE. The positions of DS, S
and S dimer are indicated by the upper, lower and middle arrows, respectively, on the right side.
Molecular weight markers were run in lane ‘M’; their sizes (in kDa) are indicated on the left.
(TIF)
S4 Fig. DSV4-induced DENV-specific antibody titers in macaques. (A) Groups of six
macaques (macaque numbers 1–6 on x-axis) each were immunized either with DSV4/alhydro-
gel (top panel) or DSV4/alhydrogel + MPLA (bottom panel) on days 0, 30 and 84. Individual
sera collected two weeks after the final immunization (day 98) were analyzed by indirect
ELISA using the following 5 recombinant proteins as coating antigens: EDIII-1 (magenta);
EDIII-2 (green); EDIII-3 (blue), EDIII-4 (black) and S (grey) proteins. Data shown are the
averages of two separate experiments. (B) Sera from macaques, immunized as described in ‘A’
(top panel: DSV4/alhydrogel; bottom panel: DSV4/alhydrogel + MPLA) were collected on
days 42, 84, 98 and 119 (x-axis) and FNT50 titers (y-axis) against the four DENV serotypes
(DENV-1: magenta; DENV-2: green; DENV-3: blue; and DENV-4: black) were determined
separately for each of the six macaques (represented by the six panels in each row). Each data
point represents the average of two separate experiments.
(TIF)
S1 Table. Purification of DSV4 from 50 g induced biomass.
(DOCX)
S2 Table. Stability of DSV4 stored under different conditions.
(DOCX)
S3 Table. Comparison of multiple EDIIIs within each serotype with the EDIII sequences
used to design DSV4.
(DOCX)
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59. Züst R, Toh YX, Valdés I, Cerny D, Heinrich J, Hermida L, et al. Type I interferon signals in macro-
phages and dendritic cells control dengue virus infection: implications for a new mouse model to
test dengue vaccines. J Virol 2014; 88: 7276–7285. https://doi.org/10.1128/JVI.03827-13 PMID:
24741106
60. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against dengue
virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci
USA 2016; 113: 728–733. https://doi.org/10.1073/pnas.1522136113 PMID: 26729879
61. Pantoja P, Perez-Guzman EX, Rodriguez IV, White LJ, Gonzalez O, Serrano C, et al. Zika virus patho-
genesis in rhesus monkeys is unaffected by pre-existing immunity to dengue virus. Nature Commun
2017; 8: 15674.
62. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda GT, et al. Den-
gue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat
Immunol 2016; 17: 1102–1108. https://doi.org/10.1038/ni.3515 PMID: 27339099
63. Slon Campos JL, Poggianella M, Marchese S, Mossenta M, Rana J, Arnoldi F, et al. DNA-immunization
with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever
virus infection. PLoS ONE 2017; 12: e0181734. https://doi.org/10.1371/journal.pone.0181734 PMID:
28742857
64. Stoute JA, Slaoui M, Heppner G, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a
recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. New Eng J Med
1997; 336: 86–91. https://doi.org/10.1056/NEJM199701093360202 PMID: 8988885
